Stem Cell Therapy for Liver Disease: Can It Support Cirrhosis and Chronic Hepatitis?

In this episode, we explore how stem cell therapy for liver disease is being studied as a supportive treatment for cirrhosis and chronic hepatitis. Learn what current research reveals, who may benefit, and why stem cell therapy should complement, not replace standard liver care.

You’ll learn:

• Why the liver’s natural ability to regenerate becomes limited in chronic liver disease
• How mesenchymal stem cell (MSC) therapy may reduce inflammation and support liver repair
• What randomized clinical trials have found about stem cell therapy for liver failure
• How stem cell therapy may help patients with cirrhosis and chronic hepatitis
• Why stem cell therapy is not a replacement for a liver transplant in advanced disease
• How antiviral treatments and stem cell therapy can work together for viral hepatitis
• What realistic outcomes can patients expect from stem cell treatment
• The safety considerations and important questions to ask before exploring stem cell therapy

While stem cell therapy for liver disease continues to show encouraging results in clinical research, it is not a cure for cirrhosis or chronic hepatitis. This episode explains the current evidence, the role of regenerative medicine in liver care, and how patients can make informed decisions with their healthcare team.

Blog Link: Stem Cell Therapy For Liver Disease: Supportive Option for Cirrhosis and Chronic Hepatitis

Transcript

SPEAKER_02 0:00

Welcome to the Sarin to Cell Podcast.

SPEAKER_00 0:02

Thanks for having me back.

SPEAKER_02 0:03

So today we're getting into something really fascinating. If you take a patient who is in like severe acute on chronic liver failure, their mortality risk is just incredibly high. It's one of the most challenging things in hepatology.

SPEAKER_00 0:19

Right, it really is. It's a very grim scenario.

SPEAKER_02 0:21

Aaron Ross Powell But what if you could infuse their body with these biological messengers, not, you know, new liver cells, but microscopic cellular formen, I guess you could call them. And doing that could actually jump their survival rate by over 17% in a matter of months.

SPEAKER_00 0:36

Yeah, that's the reality we're looking at today. We are doing a deep dive into the actual clinical data behind stem cell therapy.

SPEAKER_02 0:43

Exactly. Specifically looking at it as a supportive option for chronic liver disease and cirrhosis.

SPEAKER_00 0:47

Aaron Powell And our sources for you today include this really in-depth clinical overview of stem cell therapy for liver disease, along with some background protocols from Cyrona Cell.

SPEAKER_02 0:58

Right, Cyrona Cell. They're a regenerative medicine center based out of Kuala Bumpur, Malaysia. So our mission for you on this deep dive is to basically cut through all the medical jargon and the hype.

SPEAKER_00 1:10

Because there is a lot of hype out there, unfortunately.

SPEAKER_02 1:13

So much. We want to understand how stem cell therapy actually interacts with a failing liver on a mechanical level and figure out who it really helps.

SPEAKER_00 1:22

Yeah. And I think it's crucial to state right up front that we are looking at this strictly through the lens of supportive science-led care.

SPEAKER_02 1:30

Aaron Powell Right. No miracle cures here.

SPEAKER_00 1:31

Aaron Powell Exactly. The idea of, you know, a quick fix, magical shot that cures end-stage organ failure. That's not what this is. We're talking about an advanced adjunct to standard internal medicine.

SPEAKER_02 1:42

Aaron Powell Okay, so let's start with the organ itself, because before we get into how stem cells fix the liver, you really have to understand the liver's natural superpower.

SPEAKER_00 1:50

Which is its ability to regenerate. It's actually unmatched in the human body.

SPEAKER_02 1:54

It is crazy. Like a healthy liver can recover from a short-term acute injury in literally just weeks. It just rebuilds itself. Aaron Powell Right.

SPEAKER_00 2:01

The hepatocytes just replicate and restore the functional mass. But there is a kryptonite to that superpower.

SPEAKER_02 2:07

Aaron Powell Which is chronic damage, right? Like from viral hepatitis or you know alcohol abuse or even fatty liver disease. Trevor Burrus, Jr.

SPEAKER_00 2:15

Yeah, exactly. When the damage is continuous, the natural repair system just gets completely outpaced. Trevor Burrus, Jr.

SPEAKER_02 2:20

So if I'm picturing this, it's like the liver is this incredibly efficient construction crew and they are constantly rebuilding a house.

SPEAKER_00 2:27

Aaron Powell That's a good way to look at it.

SPEAKER_02 2:29

And under normal conditions, they're great at it, but chronic injury is like this relentless daily hurricane hitting the house. Eventually the crew just runs out of standard bricks.

SPEAKER_00 2:39

Aaron Powell Yes, and they get desperate. So to keep the house standing, they just frantically start boarding up the windows with whatever rigid material they have lying around.

SPEAKER_02 2:47

Aaron Powell And in the liver's case, that rigid material is scar tissue.

SPEAKER_00 2:50

Right. The chronic inflammation triggers these stellate cells to just pump out collagen. So healthy tissue gets replaced by this stiff, non-functional scar tissue faster than the organ can rebuild.

SPEAKER_02 3:02

Which leads to cirrhosis.

SPEAKER_00 3:04

Exactly. And that cirrhosis permanently distorts the actual physical structure of the liver. The blood vessels get choked off.

SPEAKER_02 3:12

Which changes how the blood and bile flow, right?

SPEAKER_00 3:14

Yeah. It creates massive resistance. So blood trying to enter the liver backs up, which raises the pressure in the portal vein.

SPEAKER_02 3:21

Portal hypertension.

SPEAKER_00 3:22

Right. And that is what causes the really severe life-threatening symptoms like a sites, the fluid buildup. Yeah, massive fluid buildup in the abdomen or varices, which are these swollen veins that can rupture and cause internal bleeding.

SPEAKER_02 3:35

Wow. And the scary part is this whole process, the scarring, it can go on silently for years.

SPEAKER_00 3:41

That's what makes it so dangerous. You might feel fine, but by the time you actually show symptoms of portal hypertension, the structural damage to the organ is profound. The crew lost the war a long time ago.

SPEAKER_02 3:52

Okay, so the natural construction crew is completely overwhelmed. The house is a mess of scar tissue. How do stem cells actually intervene here?

SPEAKER_00 4:01

Well, most of the credible research and the clinical protocols focus on mesenchymal stem cells, right? MSCs, usually derived from bone marrow or umbilical cord tissue because they are very safe and easy to source.

SPEAKER_02 4:13

But wait, are these MSCs actually turning into new liver cells? Like are they becoming new bricks for the house?

SPEAKER_00 4:20

No, and that's a huge misconception. Yeah. They do not directly replace the damaged liver cells. The rates of them actually engrafting and becoming hepatocytes are just way too low to explain the benefits we see in patients.

SPEAKER_02 4:33

Oh wow. Wait, really? So if they aren't becoming liver cells, what on earth are they doing? Are they more like um biological foreman?

SPEAKER_00 4:41

That is exactly what they are. They show up to this chaotic, inflamed job site, but they aren't there to lay bricks. They're there to give orders.

SPEAKER_02 4:48

Okay, so what orders are they giving?

SPEAKER_00 4:50

Well, their main job is to calm down the overactive immune cells. The liver is full of these macrophages that are just screaming for more inflammation, more scar tissue.

SPEAKER_02 5:00

Right.

SPEAKER_00 5:00

The MSCs release these biochemical signals that essentially tell the immune system to stand down. It's an anti-inflammatory effect that actively slows the pace of the scarring.

SPEAKER_02 5:10

Okay, so they stop the frantic boarding up of the windows.

SPEAKER_00 5:13

Yes. And at the same time, they release all these growth factors. These molecules basically support the liver's own natural repair signals. They coax whatever healthy tissue is left to work smarter and start healing itself.

SPEAKER_02 5:28

That is wild. It's a totally supportive approach. They work on inflammation, scarring, and repair all at once instead of just targeting one thing like a normal drug.

SPEAKER_00 5:37

Exactly. It's peracrine signaling. It's a multi-pronged support system.

SPEAKER_02 5:40

Okay, so analogies and theories are great, but you need to know what happens when this is actually tested in human beings. What do the randomized trials show?

SPEAKER_00 5:50

Let's look at a major one from the sources. It was a 110-patient randomized trial focused on hepatitis B-related liver failure.

SPEAKER_02 5:57

Which, like we said earlier, is severe, high mortality.

SPEAKER_00 6:00

Very high. Half of the patients got standard medical care, and the other half got standard care plus bone marrow derived MSEs. They got them weekly for four weeks.

SPEAKER_02 6:09

Okay, and what were the results?

SPEAKER_00 6:10

At 24 weeks, the group that only got standard therapy had a survival rate of about 55.6%.

SPEAKER_02 6:17

Okay.

SPEAKER_00 6:17

But the group that received the MSEs, their survival rate jumped to 73.2%.

SPEAKER_02 6:24

Whoa, wait, that's almost a 17% jump in survival for a condition that normally just shuts the body down. That is massive.

SPEAKER_00 6:31

It really is. And there are other studies too. There was one with 12 patients who had alcohol-related cirrhosis.

SPEAKER_02 6:37

I assume they had to stop drinking first.

SPEAKER_00 6:39

Yes. Strictly alcohol free for at least six months prior. In this one, they deliver the MSCs directly via the hepatic artery right into the liver.

SPEAKER_02 6:48

Wow. So really targeted. Did it help?

SPEAKER_00 6:51

It did. Over half of them showed measurable improvement in liver function on their actual biopsies. And most had better scores on the scales we used to measure cirrhosis severity.

SPEAKER_02 7:00

Okay, what about viral causes like hep C?

SPEAKER_00 7:04

There was another trial of 40 patients with hep C related cirrhosis. Roughly half of the patients treated with MSC saw their liver enzymes return close to normal levels.

SPEAKER_02 7:13

That is incredibly promising. But you know, whenever you hear about injecting stem cells, people immediately worry about safety, especially cancer. What about long-term data?

SPEAKER_00 7:21

That's a very valid concern. One of the key studies tracked 53 treated patients and compare them to 105 matched control patients for nearly four years.

SPEAKER_01 7:31

Four years? Why does it matter that they tracked them for that long?

SPEAKER_00 7:35

Because if a cell therapy is going to cause something like tumor growth or introduce delayed complications, it might not show up in a six-month window. You need longitudinal data.

SPEAKER_02 7:45

And what did they find after four years?

SPEAKER_00 7:47

They found absolutely no meaningful difference in liver cancer rates or overall death between the two groups. It showed the treatment did not introduce long-term oncological risks.

SPEAKER_02 7:58

Okay, so we have a solid safety profile and some really exciting survival numbers.

SPEAKER_00 8:02

Right.

SPEAKER_02 8:02

But it's easy to get carried away. We really need a reality check here.

SPEAKER_00 8:06

Yes, we absolutely do. Managing expectations is critical.

SPEAKER_02 8:09

Right. So first limitation. Yeah. This does not replace a liver transplant, right? For someone with decompensated, severe cirrhosis.

SPEAKER_00 8:16

No, not at all. If you have end-stage cirrhosis, a transplant replaces the ruined organ. MSCs, as we said, only support the existing one. You cannot rebuild a totally collapsed house with foreman alone.

SPEAKER_02 8:28

So if you need a transplant, you still need a transplant. But wait waiting lists for organs are like months or years long, right?

SPEAKER_00 8:35

Aaron Powell Sadly, yes. And that is where MSCs offer genuine practical value. They serve as a bridge. By calming the inflammation, they help keep the patient stable while they wait for that donor organ.

SPEAKER_02 8:47

Okay, that makes sense. Buying time. Now, what about the viruses themselves, like HEP B or C?

SPEAKER_00 8:52

MSCs do not cure viruses. Full stop.

SPEAKER_02 8:54

So they don't kill the virus.

SPEAKER_00 8:56

Right. Modern antiviral medications, like DAAs, they are what clear the virus from your body.

SPEAKER_02 9:02

Okay, so it's like the antivirals are putting out the fire, they extinguish the flames, but the house is still completely burned and charred.

SPEAKER_00 9:09

Exactly. The antivirals don't magically reverse the existing scar tissue. So the cell therapy works alongside the antivirals to deal with the fire damage, basically.

SPEAKER_02 9:18

Aaron Ross Powell Right, to support the tissue that got wrecked while the fire was burning.

SPEAKER_00 9:22

Exactly. No current stem cell therapy completely reverses advanced cirrhosis back to a brand new liver.

SPEAKER_02 9:27

So the goal is more about steadier function tests and maybe fewer severe complications.

SPEAKER_00 9:32

Yes, things like hepatic encephalopathy, which is when liver toxins build up and affect brain function. Reducing those episodes massively improves a patient's quality of life.

SPEAKER_02 9:43

Okay, so knowing all this nuance and knowing it needs serious medical supervision, how do patients actually go about getting this treatment safely?

SPEAKER_00 9:51

Well, that brings us back to the provider and our sources, Sarona Cell.

SPEAKER_02 9:55

Right. And Kualumpur, they're a doctor-led regenerative medicine center.

SPEAKER_00 9:59

Yeah, and they support a lot of local and international patients. They get people flying in from Australia, the Middle East, all over.

SPEAKER_02 10:05

And the name is interesting, right? Sarona cell. It's named after a Celtic goddess of health and protection.

SPEAKER_00 10:11

It is, which really highlights their focus. Yeah. They're all about protective, safe, science-led care, not making these wild quick fix promises.

SPEAKER_02 10:20

Which is so needed in this space. So where do they get their stem cells from?

SPEAKER_00 10:24

They use ethically sourced, umbilical cord-derived WGMSCs, Wharton's jelly MSCs.

SPEAKER_02 10:30

Okay, so from umbilical quartz, from healthy full-term deliveries.

SPEAKER_00 10:34

Yes, strictly with donor consent. And the processing standards are incredibly high. They operate under strict BSL2, CGMP, and ISO 9001 standards.

SPEAKER_02 10:44

So massive laboratory oversight. And just to be completely clear, they do not use embryonic stem cells.

SPEAKER_00 10:51

Absolutely not. They do not use embryonic or any experimental pluripotent stem cells. It's strictly these early passage MSCs.

SPEAKER_02 10:58

Aaron Powell And how do they actually give them to the patient? Is it a a major surgery?

SPEAKER_00 11:03

Aaron Powell No, it's minimally invasive. Why? Usually through IV infusions or sometimes targeted injections, depending on the protocol.

SPEAKER_02 11:09

Aaron Powell But the thing that really stood out to me in the sources was their transparency. Like their medical team, which has experts in internal medicine, neurology, all that, they will actually evaluate you. And if they don't think it will help, they will just tell you.

SPEAKER_00 11:21

Yes, they will clearly say so and turn you away.

SPEAKER_02 11:23

It is so refreshing to hear a clinic explicitly state that they're prioritizing long-term trust over just selling a quick one-time procedure.

SPEAKER_00 11:31

It is. And it aligns perfectly with the science we just went over. Stem cells are an adjunct, not a magic cure-all. So a rigorous doctor-led evaluation is really the only ethical way to administer them.

SPEAKER_02 11:43

Okay, so to sort of summarize the journey for you today, the liver is this incredible regenerating machine, but chronic disease basically breaks its machinery with scar tissue.

SPEAKER_00 11:53

Right. And MSEs step in not as replacement bricks, but as those biological formen to calm the inflammation and support the liver's own repair signals.

SPEAKER_02 12:02

Yeah. And while it definitely doesn't replace the need for transplants or antivirals, the clinical trials show it really can offer a serious survival and stability lifeline. And places like CironaCell are providing structured ethical pathways to actually access it.

SPEAKER_00 12:17

Aaron Powell Exactly. It's a very exciting time for supportive medicine.

SPEAKER_02 12:20

Aaron Powell It really is. And it leaves me with a pretty wild thought.

SPEAKER_00 12:22

Aaron Powell Oh yeah. What's that?

SPEAKER_02 12:24

Aaron Powell Well, if MSEs work primarily by, you know, changing the inflammatory environment and signaling cells rather than replacing them, what other chronic scar tissue forming diseases in the body might respond to this exact same biological form and approach?

SPEAKER_00 12:37

Aaron Powell That is the big question. Pulmonary fibrosis, kidney disease. If we can modulate scarring there, the potential is just massive in the future.

SPEAKER_01 12:46

Aaron Powell Mind blowing.

SPEAKER_02 12:47

Well, thanks for taking this deep dive with us. See you next time.